ReviewJournal of experimental & clinical cancer research : CR2017
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research.
Review in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Design and Analysis of N-Of-1 Trials That Incorporate Sequential Monitoring.Statistics in medicine · 2025Article
- N-of-1 Trials in Cancer Drug Development.Cancer discovery · 2023Review
- Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells.Cancer immunology, immunotherapy : CII · 2022Article
- Basic principles of biobanking: from biological samples to precision medicine for patients.Virchows Archiv : an international journal of pathology · 2021Review
- Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib.Biomedicines · 2021Article
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?Journal of experimental & clinical cancer research : CR · 2020Article
- Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization.Journal of clinical medicine · 2020Article
- Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.Medicina (Kaunas, Lithuania) · 2019Review
- Power and Design Issues in Crossover-Based N-Of-1 Clinical Trials with Fixed Data Collection Periods.Healthcare (Basel, Switzerland) · 2019Article
- miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.Journal of experimental & clinical cancer research : CR · 2019Article
- Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?Frontiers in genetics · 2019Review
- Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression.Journal of experimental & clinical cancer research : CR · 2018Article
- Biobanks and scientists: supply and demand.Journal of translational medicine · 2018Article
- Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.Journal of experimental & clinical cancer research : CR · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term "Liquid dynamic medicine" in the place of "Personalized or Precision medicine". Clinical validation of the "Liquid dynamic medicine" approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.